Home Drug IndexClinical Monograph

Droxidopa Uses, Dosage, Side Effects & Price | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Droxidopa

Therapeutic Class: Sympathomimetic Agent

Subclass: Prodrug of norepinephrine (direct-acting vasopressor)

Speciality: Neurology

Schedule (India): NOT SCHEDULED

Route(s): Oral

Formulations Available in India:
NOT AVAILABLE in India (as of latest CDSCO and IP listings)

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India):

None. Droxidopa is not approved by CDSCO and is not marketed in India.

Secondary Indications – Adults Only (Off-label):

Indication	Neurogenic Orthostatic Hypotension (nOH) — OFF-LABEL
Starting dose	100 mg orally three times daily
Titration	Increase by 100 mg TID every 24–48 hours based on blood pressure response and symptom control
Usual maintenance dose	300–600 mg three times daily
Maximum dose	600 mg TID (1800 mg/day)
Duration	Chronic therapy; clinical response typically observed within 2–4 weeks
Specialist input	Required (Neurology or Internal Medicine)
Evidence basis	Phase III RCTs (NORTHERA trials); rare off-label specialist use in India

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India):

No approved paediatric indication.

Secondary Indications – Paediatric Doses (Off-label):

Parameter	Recommendation
Age restriction	Not recommended in children below 18 years
Safety & efficacy	Not established
Use	Only under clinical trial or strict specialist supervision
Routine use	NOT RECOMMENDED

RENAL ADJUSTMENT

eGFR (mL/min/1.73m²)	Recommendation
≥60 (Normal–Mild impairment)	No adjustment required
30–59 (Moderate impairment)	No adjustment required
<30 (Severe impairment)	Use with caution; initiate at lowest dose with extended titration intervals
ESRD / Dialysis	Limited data; risk of metabolite accumulation; avoid if possible

HEPATIC ADJUSTMENT

Child-Pugh Class	Recommendation
A (Mild)	No specific adjustment documented
B (Moderate)	No specific adjustment documented; use with caution
C (Severe)	Avoid — insufficient safety data; risk of exaggerated noradrenergic effects due to altered metabolism

CONTRAINDICATIONS

• Known hypersensitivity to droxidopa or any excipients

• Pheochromocytoma (risk of hypertensive crisis)

• Uncontrolled or severe tachyarrhythmias

• Active significant cardiomyopathy

• Narrow-angle glaucoma (risk of mydriasis and raised intraocular pressure)

CAUTIONS

• Supine hypertension — particularly in elderly and patients with autonomic failure

• Ischaemic heart disease or cerebrovascular disease — close blood pressure monitoring essential

• Chronic kidney disease — potential for metabolite accumulation

• History of arrhythmias — may worsen or precipitate arrhythmia

• Avoid late evening dosing — increased risk of supine hypertension during sleep

• Patients on concurrent antihypertensive therapy — balance orthostatic versus supine blood pressure

PREGNANCY

Parameter	Recommendation
Safety category	Limited human data available
Animal studies	No major teratogenicity; maternal blood pressure elevations observed
Recommendation	Use only if potential benefit clearly outweighs fetal risk
Preferred alternative	Midodrine (off-label in India; closer maternal monitoring required)
Monitoring	Serial maternal blood pressure; fetal growth assessment

LACTATION

Parameter	Recommendation
Excretion in breast milk	Unknown
Recommendation	Avoid if possible; use alternative agents
If unavoidable	Monitor infant blood pressure, feeding pattern, and behaviour
Preferred alternative	Midodrine (limited lactation data available)

ELDERLY

• Initiate at lowest dose: 100 mg three times daily

• Slow titration recommended due to increased sensitivity and higher baseline cardiovascular risk

• Monitor both supine and standing blood pressure closely

• Elevated risk of supine hypertension, falls, cardiac events, and cognitive disturbance with blood pressure fluctuations

• Careful assessment for postural symptoms at each visit

MAJOR DRUG INTERACTIONS

Interacting Drug	Mechanism / Effect	Recommendation
MAO inhibitors (non-selective)	Impaired norepinephrine metabolism → hypertensive crisis	AVOID combination
Linezolid	MAO inhibition → serotonergic and hypertensive risk	AVOID combination
Carbidopa / DOPA-decarboxylase inhibitors	Reduced conversion of droxidopa to norepinephrine → decreased efficacy	Avoid or use with caution; may require higher droxidopa doses
SNRIs / TCAs	Potentiation of sympathomimetic effects; serotonin syndrome risk	AVOID or use with extreme caution

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Management
Levodopa	Additive dopaminergic effects	Monitor blood pressure and symptoms
Entacapone	Enhanced peripheral and central noradrenaline effects	Monitor closely
Antihypertensives	Reduced efficacy; balance needed between orthostatic and supine hypertension	Individualise therapy; frequent BP monitoring
Alpha-blockers / Beta-blockers	May blunt or unmask pressor response	Monitor blood pressure closely
Corticosteroids	May enhance vasopressor effect	Monitor blood pressure
SSRIs	Potential for sympathetic potentiation	Use with monitoring

COMMON ADVERSE EFFECTS

• Headache

• Dizziness

• Nausea

• Fatigue

• Hypertension (supine and/or sustained)

• Urinary tract infection (may relate to underlying autonomic dysfunction)

SERIOUS ADVERSE EFFECTS

• Severe supine hypertension — may necessitate dose reduction or discontinuation

• Tachyarrhythmias

• Ischaemic stroke (rare; associated with excessive blood pressure elevation)

• Myocardial ischaemia / angina — especially in patients with underlying coronary artery disease

• Neuroleptic malignant syndrome-like symptoms (very rare)

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	ECG; supine and standing blood pressure; renal function; hepatic function
During titration	Daily supine and standing blood pressure (home or nursing supervision); assess for headache, palpitations, arrhythmia symptoms
Long-term	Blood pressure at various times of day including overnight supine; annual ECG or if cardiac symptoms develop; renal function every 6–12 months

BRANDS AVAILABLE IN INDIA

NOT AVAILABLE in India (no CDSCO-approved brands as per latest database)

PRICE RANGE (INR)

Not applicable — Not marketed in India

Reference: Approximate international price equivalent ₹400–700 per 100 mg capsule (US pricing)

CLINICAL PEARLS

• Reserve for specialist-managed neurogenic orthostatic hypotension unresponsive to volume expansion and midodrine

• Supine hypertension can occur even at low doses — counsel patients to elevate head of bed by 10–15 degrees during sleep

• Avoid evening dosing to minimise nocturnal supine hypertension

• Not indicated for non-neurogenic causes of orthostatic hypotension

• Clinical improvement may require 1–2 weeks; individualise dosing based on response

• Consider deprescribing if no sustained benefit observed after adequate dose optimisation

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.